Topical Curaderm^BEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes

Bill E. Cham

Australasian Medical Research, Port Vila, Republic of Vanuatu.

DOI: 10.4236/ijcm.2013.45041                

Abstract

Approximately 5 to 10 percent of all skin cancers occur in the periocular region. Basal cell carcinoma is the most frequent malignant periocular tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Nonmelanoma skin tumors at the periocular area often cause disfigurement with destruction of soft conjunctival tissue. Many therapeutic methods have been recommended to combat the morbidity and mortality associated with these lesions. Excisions with frozen-section control or Mohs micrographic surgery are regarded as the gold-standard treatments for periocular basal cell and squamous cell carcinomas. However, these treatment modalities have various limitations and reconstruction surgery is often associated with these treatment options. The chemotherapeutic agents solasodine rhamnosides in a cream formulation Curaderm^BEC5 are specific, effective and safe treatments for nonmelanoma skin cancers with excellent cosmesis. The antineoplastic mode of action is by apoptosis. In this review it is shown that Curaderm^BEC5 also treats periocular basal cell carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and no reconstructive surgery is required.

Keywords

Periocular Skin Cancers; Curaderm^BEC5; Apoptosis; Solamargine; Basal Cell Carcinoma; Squamous Cell Carcinoma; Cosmesis; Solanum

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	S. J. Miller, “Biology of Basal Cell Carcinoma (Part 1),” Journal of the American Academy of Dermatology, Vol. 24, No. 1, 1991, pp. 1-13.
[2]	A. N. Crowson, “Basal Cell Carcinoma: Biology, Morphology and Clinical Implications,” Modern Pathology, Vol. 19, No. S2, 2006, pp. 5127-5147. doi:10.1038/modpathol.3800512
[3]	D. L. Miller and M. A. Weinstock, “Nonmelanoma Skin Cancer in the United States: Incidence,” Journal of the American Academy of Dermatology, Vol. 30, No. 5, 1994, pp. 774-778.
[4]	D. H. Brewster, L. A. Bhatti, J. H. C. Inglis, E. R. Nairn and V. R. Doherty, “Recent Trends in Incidence of Nonmelanoma Skin Cancers in the East of Scotland, 19922003,” British Journal of Dermatology, Vol. 156, No. 6, 2007, pp. 1295-1300. doi:10.1111/j.1365-2133.2007.07892.x
[5]	American Academy of Dermatology, “Squamous Cell Carcinoma,” 2012. http://www.aad.org/skin-conditions/dermatology-a-to-z/squamous-cell-carcinoma
[6]	R. S. Stern, “Prevalence of a History of Skin Cancer in 2007: Results of an Incidence-Based Model,” Archives Dermatology, Vol. 146, No. 3, 2010, pp. 279-282. doi:10.1001/archdermatol.2010.4
[7]	American Cancer Society, “Cancer Facts & Figures,” 2012.
[8]	R. I. Ceilley and J. Q. del Rosso, “Current Modalities and New Advances in the Treatment of Basal Cell Carcinoma,” International Journal of Dermatology, Vol. 45, No. 5, 2006, pp. 489-498. doi:10.1111/j.1365-4632.2006.02673.x
[9]	B. E. Cham, “Intralesion and Curaderm BEC5 Topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared,” International Journal Clinical Medicine, Vol. 3, No. 2, 2012, pp. 115-124. doi:10.4236/ijcm.2012.32024
[10]	B. E. Cham, “Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports,” International Journal Clinical Medicine, Vol. 2, No. 4, 2011, pp. 473-477. doi:10.4236/ijcm.2011.24080
[11]	S. Punjabi, L. J. Cook, P. Kersey, R. Marks and R. Cerio, “Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma. A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study,” International Journal Dermatology, Vol. 47, 2008, pp. 78-82. doi:10.1111/j.1365-4632.2007.03363.x
[12]	B. E. Cham and H. M. Meares, “Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man,” Cancer Letters, Vol. 36, No. 2, 1987, pp. 111-118. doi:10.1016/0304-3835(87)90081-4
[13]	B. E. Cham, B. Daunter and R. Evans, “Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides,” Cancer Letters, Vol. 59, No. 3, 1991, pp. 183-192. doi:10.1016/0304-3835(91)90140-D
[14]	B. E. Cham, “Solasodine Glycosides as Anti-Cancer Agents: Pre-Clinical and Clinical Studies,” Asia Pacific Journal Pharmacology, Vol. 9, No. 2, 1994, pp. 113-118.
[15]	B. E. Cham, “Solasodine Rhamnosyl Glycosides in a Cream Formulation Is Effective for Treating Large and Troublesome Skin Cancers,” Research Journal Biological Science, Vol. 2, No. 7, 2007, pp. 749-761.
[16]	B. E. Cham, “Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers,” Research Journal Biological Science, Vol. 2, No. 7, 2007, pp. 503-514.
[17]	T. R. Chase, “CuradermBEC5 for Skin Cancers, Is It? An Overview,” Journal Cancer Therapy, Vol. 2, No. 5, 2011, pp. 728-745. doi:10.4236/jct.2011.25099
[18]	L. H. Goldberg, J. M. Landau, M. N. Moody and I. J. Vergilis-Kalner, “Treatment of Bowen’s Disease on the Penis with Low Concentration of a Standard Mixture of Solasodine Glycosides and Liquid Nitrogen,” Dermatologic Surgery, Vol. 37, 2011, pp. 858-861. doi:10.1111/j.1524-4725.2011.02014.x
[19]	B. E. Cham and L. Wilson, “HPLC of Glycoalkaloids from Solanum sodomaeum,” Planta Medica, Vol. 53, No. 1, 1987, pp. 34-36. doi:10.1055/s-2006-962612
[20]	B. E. Cham, M. Gilliver and L. Wilson, “Antitumour Effects of Glycoalkaloids Isolated from Solanum sodomaeum L.,” Planta Medica, Vol. 53, No. 1, 1987, pp. 34-36. doi:10.1055/s-2006-962612
[21]	B. E. Cham and B. Daunter, “Solasodine Glycosides. Selective Cytotoxicity for Cancer Cells and Inhibition of Cytotoxicity by Rhamnose in Mice with Sarcoma 180,” Cancer Letters, Vol. 55, 1990, pp. 221-225. doi:10.1016/0304-3835(90)90122-E
[22]	B. E. Cham and T. R. Chase, “Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells, Do They Also Prime the Immune System Resulting in Long Term Protection against Cancer?” Planta Medica, Vol. 78, 2012, pp. 349-353. doi:10.1055/s-0031-1298149
[23]	B. E. Cham, “Monograph on the Compound BEC,” Drugs of the Future, Vol. 13, 1988, pp. 714-716.
[24]	B. E. Cham, “The Eggplant Cancer Cure. A Treatment for Skin Cancer and New Hope for Other Cancers from Nature’s Pharmacy,” Smart Publications, Petaluma, 2007, pp. 1-122.
[25]	B. E. Cham, “Inspired by Nature, Proven by Science. The New Generation Cancer Treatment That Causes Cancer Cells to Commit Suicide,” in Preparation.
[26]	L. A. E. Sussman and D. F. Liggins, “Incompletely Excised Basal Cell Carcinoma a Management Dilemma?” Aust NZ Journal Surgery, Vol. 66, 1996, pp. 276-278. doi:10.1111/j.1445-2197.1996.tb01184.x
[27]	B. Daunter and B. E. Cham, “Solasodine Glycosides, in Vitro Preferential Cytotoxicity for Human Cancer Cells,” Cancer Letters, Vol. 55, No. 3, 1990, pp. 209-220. doi:10.1016/0304-3835(90)90121-D
[28]	R. J. Lipscombe, S. J. Carter and M. Ruane, “Rhamnose Binding Protein,” United States Patent 6, 930, 171 B2, 2005.
[29]	L. Y. Shiu, L. C. Chang, C. H. Liang, Y. S. Huang, H. M. Sheu and K. W. Kuo, “Solamargine Induces Apoptosis and Sensitizes Breast Cancer Cells to Cisplatin,” Food Chemical Toxicology, Vol. 45, No. 11, 2007, pp. 2155-2164. doi:10.1016/j.fct.2007.05.009
[30]	C. H. Liang, L. Y. Shiu, L. C. Chang, H. M. Sheu and K. W. Kuo, “Solamargine Upregulation of Fas, Downregulation of HER 2, and Enhancement of Cytotoxicity Using Epirubicin in NSCLC Cells,” Molecular Nutrition Food Research, Vol. 51, 2007, pp. 999-1005. doi:10.1002/mnfr.200700044
[31]	L. Y. Shiu, C. H. Liang, L. C. Chang, H. M. Sheu, E. M. Tsai and K. W. Kuo, “Solamargine Induces Apoptosis and Enhances Susceptibility to Trastazumab and Epirubicin in Breast Cancer Cells with Low or High Expression Levels of HER2/neu,”Bioscience Reports, Vol. 29, No. 1, 2009, pp. 35-45. doi:10.1042/BSR20080028
[32]	L. Sun, Y. Zhao, X. Li, H. Yuan, A. Cheng and H. Lou, “A Lysosomal-Mitochondrial Death Pathway Is Induced by Solamargine in Human K562 Leukemia Cells,” Toxicology in Vitro, Vol. 24, No. 6, 2010, pp. 1504-1511. doi:10.1016/j.tiv.2010.07.013
[33]	L. Sun, Y. Zhao, H. Yuan, X. Li, A. Cheng and H. Lou, “Solamargine, a Steroidal Alkaloid Glycoside, Induces Oncosis in Human K562 Leukemia and Squamous Cell Carcinoma KB Cells,” Cancer Chemotherapy Pharmacology, Vol. 65, No. 4, 2010, pp. 1125-1130.
[34]	X. Li, Y. Zhao, W. K. K. Wu, S. Liu, M. Cui and H. Lou, “Solamargine Induces Apoptosis Associated with p53 Transcription-Dependent and Transcription-Independent Pathways in Human Osteosarcoma U20S Cells,” Life Science, Vol. 88, No. 7-8, 2011, pp. 314-321.
[35]	B. E. Cham, “Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study,” Journal Cancer Therapy, Vol. 4, No. 2, 2013, pp. 588-596. doi:10.4236/jct.2013.42076
[36]	B. E. Cham, “Drug Therapy: Solamargine and Other Solasodine Rhamnosyl Glycosides as Anticancer Agents,” Modern Chemotherapy, Vol. 2, No. 2, 2013, pp. 33-49. doi:10.4236/mc.2013.22005